Sushima Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
- Paid Up Capital ₹ 2.00 M
- Company Age 29 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 24.55%
- Profit Growth 23.58%
- Ebitda 27.74%
- Net Worth 33.92%
- Total Assets 27.26%
About Sushima Pharmaceuticals
Sushima Pharmaceuticals Private Limited (SPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 17 July 1995 and has a history of 29 years and six months. Its registered office is in Udham Singh Nagar, Uttarakhand, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 2.00 M, as per Ministry of Corporate Affairs (MCA) records.
Mamta Goel, Vikas Garg, Shagun Goel, and Two other members serve as directors at the Company.
Company Details
- Location
Udham Singh Nagar, Uttarakhand, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U74899UR1995PTC000768
- Company No.
000768
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Jul 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Who are the key members and board of directors at Sushima Pharmaceuticals?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mamta Goel  | Director | 17-Jul-1995 | Current |
| Vikas Garg | Director | 17-Jul-1995 | Current |
| Shagun Goel | Director | 17-Jul-1995 | Current |
| Piyush Goel | Director | 17-Jul-1995 | Current |
| Deepak Goel | Director | 17-Jul-1995 | Current |
Financial Performance of Sushima Pharmaceuticals.
Sushima Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 24.55% increase. The company also saw a substantial improvement in profitability, with a 23.58% increase in profit. The company's net worth Soared by an impressive increase of 33.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sushima Pharmaceuticals?
In 2022, Sushima Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Veterinary Distributors Private LimitedVikas Garg, Piyush Goel and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sushima Pharmaceuticals?
Unlock and access historical data on people associated with Sushima Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sushima Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sushima Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.